1. Home
  2. CGEM vs JQC Comparison

CGEM vs JQC Comparison

Compare CGEM & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$12.11

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

HOLD

Current Price

$5.04

Market Cap

753.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
JQC
Founded
2016
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
671.7M
753.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CGEM
JQC
Price
$12.11
$5.04
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$28.00
N/A
AVG Volume (30 Days)
1.4M
714.6K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
11.13%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$4.82
52 Week High
$13.33
$5.65

Technical Indicators

Market Signals
Indicator
CGEM
JQC
Relative Strength Index (RSI) 63.92 44.52
Support Level $10.01 $5.00
Resistance Level $13.10 $5.08
Average True Range (ATR) 1.21 0.05
MACD 0.09 0.00
Stochastic Oscillator 67.02 45.93

Price Performance

Historical Comparison
CGEM
JQC

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

Share on Social Networks: